Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 280, Issue 2 49-2, 2001, Pages

  Duffy, Stephen J ^a   Gokce, Noyan ^a   Holbrook, Monika ^a   Hunter, Liza M ^a   Biegelsen, Elizabeth S ^a   Huang, Annong ^a   Keaney Jr , John F ^a   Vita, Joseph A ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Antioxidants; Endothelium derived factors; Nitric oxide

Indexed keywords

ASCORBIC ACID; GLYCERYL TRINITRATE; PLACEBO;

ADULT; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASOMOTOR REFLEX;

EID: 0035013889     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2001.280.2.h528     Document Type: Article

References (45)

1. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, and Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 336: 1117-1124, 1997.
2. 2α, in rabbit lung in situ. Am J Physiol Heart Circ Physiol 263: H660-H663, 1992.
3. Beetens JR and Herman AG. Vitamin C increases the formation of prostacyclin by aortic rings from various species and neutralizes the inhibitory effect of 15-hydroperoxy-arachidonic acid. Br J Pharmacol 80: 249-254, 1983.
4. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, and Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25: 305-313, 1995.
5. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 10: 1025-1031, 1992.
6. Celermajer DS, Sorensen KE, Bull C, Robinson J, and Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24: 1468-1474, 1994.
7. Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ, Parmar K, Bewley SJ, Shennan AH, Steer PJ, and Poston L. Effect of antioxidants on the occurrence of preeclampsia in women at increased risk: a randomised trial. Lancet 354: 810-816, 1999.
8. Collins R, Peto R, MacMahon S, Hebert P, Fiebacb NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, and Hennekens CH. Blood pressure, stroke, and coronary heart disease. 2. Short-term reductions in blood pressure: overview of randomised trials in their epidemiological context. Lancet 335: 827-838, 1990.
9. Creager MA and Roddy MA. Effects of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 24: 499-505, 1994.
10. Duffy SJ, Gokce N, Holbrook M, Huang A, Frei B, Keaney JF Jr, and Vita JA. Treatment of hypertension with ascorbic acid. Lancet 354: 2048-2049, 1999.
11. Enstrom JE, Kanim LE, and Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 3: 194-202, 1992.
12. FitzGerald GA, Brash AR, Falardeau P, and Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 68: 1272-1275, 1981.
13. Frei B, England L, and Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 86: 6377-6381, 1989.
14. Friedewald WT, Levy RI, and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
15. Gale CR, Martyn CN, Winter PD, and Cooper C. Vitamin C and risk of death from stroke and coronary heart disease in cohort of elderly people. Br Med J 310: 1563-1566, 1995.
16. Galley HF, Thornton J, Howdle PD, Walker BE, and Webster NR. Combination oral antioxidant supplementation reduces blood pressure. Clin Sci (Colch) 92: 361-365, 1997.
17. Gokce N, Holbrook M, Biegelsen ES, Duffy SJ, Hunter LM, Swerdloff PL, and Vita JA. Conduit artery endothelial function is impaired equally in white and African-American hypertensives (Abstract). Circulation 100: I-834, 1999.
18. Gokce N, Keaney JF Jr, Frei B, Holbrook M, Olesiak M, Zachariah BJ, Leeuwenburgh C, Heinecke JW, and Vita JA. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 99: 3234-3240, 1999.
19. Gokce N, Keaney JF Jr, and Vita JA. Endotheliopathies: clinical manifestations of endothelial dysfunction. In: Thrombosis and Hemorrhage (2nd ed.), edited by Loscalzo J and Shafer AI. Baltimore, MD: Williams & Wilkins, 1998, p. 901-924.
20. Haynes WG, Noon JP, Walker BR, and Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 11: 1375-1380, 1993.
21. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G, and Oshima T. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, β-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multi-center study. J Am Coll Cardiol 35: 284-291, 2000.
22. Hishikawa K and Luscher TF. Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation 96: 3610-3616, 1997.
23. Howard AB, Alexander RW, Nerem RM, Griendling KK, and Taylor WR. Cyclic strain induces an oxidative stress in endothelial cells. Am J Physiol Cell Physiol 272: C421-C427, 1997.
24. Iiyama K, Nagano M, Yo Y, Nagano N, Kamide K, Higaki J, Mikami H, and Ogihara T. Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 132: 779-782, 1996.
25. Jackson TS, Xu A, Vita JA, and Keaney JF Jr. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res 83: 916-922, 1998.
26. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, and Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 93: 1107-1113, 1996.
27. Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC, and Creager MA. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 78: 1210-1214, 1996.
28. Mayer B, Moser R, Gleispach H, and Kukovetz WR. Possible inhibitory function of endogenous 15-hydroperoxyeicosatetraenoic acid on prostacyclin formation in bovine aortic endothelial cells. Biochim Biophys Acta 875: 641-653, 1986.
29. McCarron DA, Morris CD, Henry HJ, and Stanton JL. Blood pressure and nutrient intake in the United States. Science 224: 1392-1398, 1984.
30. McNamara DB, Hussey JL, Kerstein MD, Rosenson RS, Hyman AL, and Kadowitz PJ. Modulation of prostacyclin synthetase and unmasking of PGE2 isomerase in bovine coronary arterial microsomes. Biochem Biophys Res Commun 118: 33-39, 1984.
31. Muiesan ML, Salvetti M, Monteduro C, Rizzoni D, Zulli R, Corbellini C, Brun C, and Agabiti-Rosei E. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 33: 575-580, 1999.
32. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, and Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 88: 10045-10048, 1991.
33. Panza JA, Quyyumi AA, Brush JE Jr, and Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323: 22-27, 1990.
34. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, and Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contributions to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996.
35. Reaven GM, Lithell H, and Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334: 374-381, 1996.
36. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126, 1999.
37. Salonen JT, Salonen R, Ihanainen M, Parviainen M, Seppanen R, Kantola M, Seppanen K, and Rauramaa R. Blood pressure, dietary fats, and antioxidants. Am J Clin Nutr 48: 1226-1232, 1988.
38. Schiffrin EL and Deng L-Y. Comparison of the effects of angiotensin I-converting enzyme inhibition and β-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 25: 699-703, 1995.
39. Sherman DL, Keaney JF Jr, Biegelsen ES, Duffy SJ, Coffman JD, and Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension 35: 936-941, 2000.
40. Solzbach U, Hornig B, Jeserich M, and Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 96: 1513-1519, 1997.
41. Taddei S, Virdis A, Ghiadoni L, Magagna A, and Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 97: 2222-2229, 1998.
42. Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, Ganz P, and Alexander RW. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 87: 86-93, 1993.
43. Treasure CB, Manoukian SV, Klein JL, Vita JA, Nabel EG, Renwick GH, Selwyn AP, Alexander RW, and Ganz P. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res 71: 776-781, 1992.
44. Vita JA, Frei B, Holbrook M, Gokce N, Leaf C, and Keaney JF Jr. L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J Clin Invest 101: 1408-1414, 1998.
45. Vogel RA, Corretti MC, and Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 77: 37-40, 1996.